
UPDATES ON A LITIGATION PROCEEDING IN THE PEOPLE'S REPUBLIC OF CHINA

1. OUE Lippo Healthcare Limited (the “**Company**” and together with its subsidiaries, the “**Group**”) refers to its announcements dated 24 December 2021 and 17 June 2022 on the creditor subrogation claim by Wuxi Hongshen Pharmacy Co., Ltd (“**Wuxi Hongshen**”) in the People’s Republic of China (“**PRC**”) against Wuxi Yilin Real Estate Development Co., Ltd (“**Wuxi Yilin Real Estate**”), a subsidiary of the Company (the “**Subrogation Claim**”).
2. As announced on 24 December 2021 and 17 June 2022:
 - (a) the People’s Court of Xinwu District, Wuxi released a Judgment in the Subrogation Claim on 14 December 2021 agreeing with the points raised by Wuxi Hongshen, and ordering Wuxi Yilin Real Estate to pay the sum of RMB 1,513,284.18 plus interest and costs to Wuxi Hongshen;
 - (b) on 24 December 2021, Wuxi Yilin Real Estate filed an appeal against the Judgment issued by the People’s Court of Xinwu District, Wuxi; and
 - (c) on 13 June 2022, the Wuxi Intermediate People’s Court released a Judgment dismissing the appeal, and affirming the decision by the People’s Court of Xinwu District, Wuxi.
3. As announced on 17 June 2022, the Company was seeking legal advice from its PRC Counsel to address Wuxi Hongshen’s claims. After obtaining legal advice and as at the date of this announcement, Wuxi Yilin Real Estate has caused the sum of RMB 1,513,284.18 (equivalent to approximately S\$307,499.34 as at an exchange rate of RMB 100 = S\$20.32 as at 2 September 2022) plus interest and costs to be paid to Wuxi Hongshen pursuant to the Judgment rendered by the Wuxi Intermediate People’s Court. As such, Wuxi Hongshen’s claims have been fully satisfied, and no further sums are due and owing from Wuxi Yilin Real Estate to Wuxi Hongshen.
4. The above settlement is not expected to have a material impact on the earnings per share and net asset value per share of the Group for the current financial year ending 31 December 2022.

By Order of the Board
OUE Lippo Healthcare Limited

Mr. Yet Kum Meng
Chief Executive Officer and Executive Director
02 September 2022

*This announcement has been reviewed by the Company's sponsor, PrimePartners Corporate Finance Pte. Ltd. (the "**Sponsor**"). It has not been examined or approved by the Singapore Exchange Securities Trading Limited (the "**Exchange**") and the Exchange assumes no responsibility for the contents of this document, including the correctness of any of the statements or opinions made or reports contained in this document.*

The contact person for the Sponsor is Ms. Foo Jien Jieng, 16 Collyer Quay, #10-00 Collyer Quay Centre, Singapore 049318, sponsorship@ppcf.com.sg.